New drug study aims to help people with debilitating muscle disease regain daily function

NCT ID NCT06909253

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is observing how well the drug ravulizumab helps adults in Poland with generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness. Researchers will follow 50 patients for about 3 years to see if the treatment improves their ability to perform daily activities, reduces symptoms, and enhances their quality of life. The study is not testing a new treatment but collecting real-world data on how patients already receiving this medication fare over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Bydgoszcz, Poland
Research Site
RECRUITING

Gdansk, Poland
Research Site
NOT_YET_RECRUITING

Katowice, Poland
Research Site
RECRUITING

Katowice, Poland
Research Site
RECRUITING

Krakow, Poland
Research Site
RECRUITING

Lodz, Poland
Research Site
RECRUITING

Lublin, Poland
Research Site
WITHDRAWN

Poznan, Poland
Research Site
NOT_YET_RECRUITING

Poznan, Poland
Research Site
RECRUITING

Szczecin, Poland
Research Site
NOT_YET_RECRUITING

Szczecin, Poland
Research Site
RECRUITING

Warsaw, Poland
Research Site
NOT_YET_RECRUITING

Warsaw, Poland
Research Site
RECRUITING

Wroclaw, Poland

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS, GENERALIZED